SRZN Stock Price, Surrozen, Inc. Quote, Chart

Market Summary

USD9.32-0.43

Market Closed

-4.41%

SRZN Alerts

2 major insider buys recently.

SRZN Stock Price

View Fullscreen

SRZN RSI Chart

SRZN Valuation

Market Cap

29.8M

Price/Earnings (Trailing)

-0.69

Price/Sales (Trailing)

2.82

Price/Free Cashflow

-0.73

SRZN Price/Sales (Trailing)

SRZN Profitability

Return on Equity

-113.44%

Return on Assets

-93.39%

Free Cashflow Yield

-136.85%

SRZN Fundamentals

SRZN Revenue

Revenue (TTM)

12.5M

SRZN Earnings

Earnings (TTM)

-43.0M

Earnings Growth (Yr)

-1.1K%

Earnings Growth (Qtr)

13.94%

Breaking Down SRZN Revenue

Last 7 days

-17.9%

Last 30 days

-27.1%

Last 90 days

-0.8%

Trailing 12 Months

1208.6%

How does SRZN drawdown profile look like?

SRZN Financial Health

Current Ratio

5.75

SRZN Investor Care

Buy Backs (1Y)

12.95%

Diluted EPS (TTM)

-38.28

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	0	0	0	12.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Surrozen, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 04, 2024	column group iii gp, lp	bought	1,591,090	15.5	102,651	-
Apr 04, 2024	column group iii gp, lp	bought	1,408,900	15.5	90,897	-
Apr 04, 2024	kutzkey tim	bought	1,591,090	15.5	102,651	-
Apr 04, 2024	kutzkey tim	bought	1,408,900	15.5	90,897	-
Apr 04, 2024	parker craig c	bought	-	-	1,474	chief executive officer
Apr 04, 2024	williams charles o	bought	-	-	1,474	cfo and coo
Dec 15, 2023	li yang	acquired	11,822	5.67	2,085	exec. vice president, research
Dec 15, 2023	parker craig c	acquired	11,600	5.67	2,046	chief executive officer
Dec 15, 2023	williams charles o	acquired	11,822	5.67	2,085	chief financial officer
Jun 15, 2023	yeh wen-chen	acquired	6,702	0.38	17,638	chief scientific officer

Which funds bought or sold SRZN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	new	-	305,603	305,603	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-238,972	-	-%
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-6,000	-	-%
Feb 26, 2024	PERCEPTIVE ADVISORS LLC	added	1,400	-3,334	3,333	-%
Feb 14, 2024	Royal Bank of Canada	sold off	-100	-	-	-%
Feb 14, 2024	Altitude Crest Partners Inc.	new	-	7,691	7,691	-%
Feb 14, 2024	BRIDGER MANAGEMENT, LLC	added	1,400	-10,127	9,053	-%
Feb 14, 2024	BRIDGER MANAGEMENT, LLC	sold off	-100	-30,233	-	-%
Feb 14, 2024	Royal Bank of Canada	new	-	1,000	1,000	-%
Feb 14, 2024	ArrowMark Colorado Holdings LLC	new	-	523,669	523,669	0.01%

Are Funds Buying or Selling SRZN?

Are funds buying SRZN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SRZN

No. of Funds

SRZN Alerts

2 major insider buys recently.

Unveiling Surrozen, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 15, 2024	ra capital management, l.p.	9.99%	323,662	SC 13G
Apr 08, 2024	column group iii gp, lp	34.2%	1,236,384	SC 13D/A
Feb 14, 2024	alyeska investment group, l.p.	9.99%	203,629	SC 13G
Feb 09, 2024	goldman sachs group inc	7.9%	172,666	SC 13G
Feb 07, 2024	bml investment partners, l.p.	0.0%	0	SC 13G/A
Feb 14, 2023	baker bros. advisors lp	2.3%	833,333	SC 13G/A
Feb 13, 2023	column group iii gp, lp	31.5%	9,414,795	SC 13D/A
Feb 02, 2023	bml investment partners, l.p.	5.6%	1,669,037	SC 13G
Feb 02, 2023	regents of the university of california	5.93%	2,081,453	SC 13G/A
Dec 15, 2022	consonance capital management lp	0%	0	SC 13D/A

Recent SEC filings of Surrozen, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 15, 2024	SC 13G	Major Ownership Report
Apr 10, 2024	10-K	Annual Report
Apr 10, 2024	S-8	Employee Benefits Plan
Apr 08, 2024	4	Insider Trading
Apr 08, 2024	4	Insider Trading
Apr 08, 2024	4	Insider Trading
Apr 08, 2024	4	Insider Trading
Apr 08, 2024	SC 13D/A	13D - Major Acquisition
Apr 02, 2024	NT 10-K	NT 10-K
Apr 02, 2024	8-K	Current Report

Peers (Alternatives to Surrozen, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.7B	6.8B	-0.04%	-27.89%	-8.41	5.79	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.5B	1.8B	-1.63%	-28.69%	-42.01	10.12	76.23%	61.08%
BMRN	17.2B	2.4B	8.39%	-9.36%	102.31	7.09	15.42%	18.43%
INCY	11.9B	3.7B	-8.82%	-29.04%	20	3.23	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-8.69%	-36.86%	-11.82	15.75	425.83%	18.94%
BBIO	4.4B	-	-8.20%	68.33%	-6.81	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-8.92%	-2.36%	-13.62	12.04	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.30%	-24.47%	-9.88	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-11.77%	-45.95	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-3.36%	-14.10%	25.63	4.6	85.90%	-14.05%
NVAX	557.0M	983.7M	-24.76%	-57.93%	-1.02	0.57	-50.36%	17.16%
CRBP	432.8M	881.7K	-5.56%	294.36%	-9.7	466.16	-77.61%	-5.33%
INO	225.3M	4.9M	-10.24%	-14.54%	-1.67	46.29	-54.97%	51.72%
IBIO	6.8M	2.1M	86.67%	92.16%	-0.25	2.14	-13.45%	66.37%

Surrozen, Inc. News

Latest updates

Surrozen, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)		(In Thousands)
Description	(%) Q/Q	2023Q4	2022Q4
Operating Expenses	-33.7%	10.00	15.00
S&GA Expenses	-100.0%	-	5.00
R&D Expenses	-35.4%	6.00	9.00
Net Income	-1087.8%	-8.95	-0.75
Net Income Margin	-19.5%	-3.44*	-2.88*
Free Cashflow	-2011.5%	-7.35	-0.35

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-14.6%	46.00	54.00	64.00	74.00	89.00	91.00	104	118	137	151	93.00	93.00	62.00	52.00	42.00
Current Assets	-14.9%	41.00	48.00	58.00	67.00	81.00	83.00	95.00	96.00	105	114	1.00	1.00	50.00	-	29.00
Cash Equivalents	8.1%	37.00	34.00	36.00	28.00	25.00	26.00	17.00	14.00	33.00	61.00	19.00	23.00	35.00	59.00	30.00
Net PPE	-20.7%	2.00	2.00	3.00	3.00	4.00	4.00	4.00	5.00	5.00	5.00	5.00	-	6.00	-	7.00
Liabilities	-3.5%	8.00	8.00	9.00	11.00	13.00	14.00	14.00	15.00	27.00	27.00	10.00	7.00	15.00	-	13.00
Current Liabilities	7.1%	7.00	7.00	6.00	8.00	10.00	9.00	9.00	8.00	14.00	13.00	2.00	1.00	7.00	0.00	4.00
Shareholder's Equity	-16.7%	38.00	46.00	55.00	63.00	76.00	77.00	90.00	103	110	124	23.00	35.00	47.00	58.00	29.00
Retained Earnings	-4.2%	-221	-212	-202	-193	-178	-177	-164	-150	-142	-127	-5.94	-2.36	-88.00	0.00	-55.28
Additional Paid-In Capital	0.5%	260	258	257	256	255	256	255	254	252	251	11.00	7.00	135	0.00	1.00
Shares Outstanding	1.2%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	-	1.00	1.00	-
Float	-	-	-	12.00	-	-	-	76.00	-	-	-	81.00	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Cashflow From Operations	27.5%	-7,348	-10,133	-8,719	-14,200	-200	-14,100	-11,400	-18,400	-11,543	-14,058	-12,912	-10,300	-933	-7,537	-	-
Share Based Compensation	28.4%	1,172	913	1,158	1,129	1,545	1,077	979	916	693	616	532	475	187	140	-	-
Cashflow From Investing	24.2%	9,500	7,646	17,249	17,328	1,913	22,831	13,977	-412	-16,621	-68,285	8,640	-1,442	-92,000	-247	-	-
Cashflow From Financing	1184.6%	141	-13.00	187	-39.00	-2,549	-13.00	-3.00	-	159	124,589	-314	196	93,921	13.00	-	-

SRZN Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Collaboration and license revenue	$ 0	$ 12,500
Operating expenses:
Research and development	27,230	37,013
General and administrative	15,798	19,826
Restructuring	2,752	0
Total operating expenses	45,780	56,839
Loss from operations	(45,780)	(44,339)
Interest income	2,340	781
Other income, net	398	7,554
Net loss	(43,042)	(36,004)
Unrealized gain (loss) on marketable securities, net of tax	241	(122)
Comprehensive loss	$ (42,801)	$ (36,126)
Net loss per share attributable to common stockholders, basic	$ (21.33)	$ (15.56)
Net loss per share attributable to common Stockholders, diluted	$ (21.33)	$ (15.56)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	2,018	2,314
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	2,018	2,314

SRZN Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 36,043	$ 24,690
Accounts receivable	2,152	1,978
Short-term marketable securities	0	51,148
Prepaid expenses and other current assets	2,937	3,489
Total current assets	41,132	81,305
Property and equipment, net	1,969	3,630
Operating lease right-of-use assets	1,889	3,268
Restricted cash	688	405
Other assets	402	827
Total assets	46,080	89,435
Current liabilities:
Accounts payable	525	658
Accrued and other liabilities	4,126	6,848
Lease liabilities, current portion	2,497	2,226
Total current liabilities	7,148	9,732
Lease liabilities, noncurrent portion	882	3,376
Warrant liability	115	326
Total liabilities	8,145	13,434
Commitments and contingencies (Note 5 and Note 14)
Stockholders’ equity:
Preferred stock, $0.0001 par value, 10,000 shares authorized; no shares issued and outstanding as of December 31, 2023 and 2022	0	0
Common stock, $0.0001 par value, 500,000 shares authorized as of December 31, 2023 and 2022; 2,063 and 2,006 shares issued and outstanding as of December 31, 2023 and 2022, respectively	0	0
Additional paid-in-capital	259,630	254,895
Accumulated other comprehensive loss	0	(241)
Accumulated deficit	(221,695)	(178,653)
Total stockholders’ equity	37,935	76,001
Total liabilities and stockholders’ equity	$ 46,080	$ 89,435

About Surrozen, Inc.

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. The company is developing antibody-based therapeutics with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcoholic hepatitis and asialoglycoprotein receptor 1; and SZN-1326, a bi-specific antibody, which is in Phase 1b clinical trial for the treatment of moderate to severe inflammatory bowel disease, Frizzled, and LRP receptors. The company also develops SZN-413, a Fzd4 targeted bi-specific antibody, which is in preclinical stage for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. was founded in 2015 and is based in South San Francisco, California.

CEO	Mr. Craig C. Parker M.B.A.
WEBSITE	surrozen.com
INDUSTRY	Biotechnology
EMPLOYEES	74

Surrozen, Inc. Frequently Asked Questions

What is the ticker symbol for Surrozen, Inc.? What does SRZN stand for in stocks?

SRZN is the stock ticker symbol of Surrozen, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Surrozen, Inc. (SRZN)?

As of Tue Apr 16 2024, market cap of Surrozen, Inc. is 29.81 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SRZN stock?

You can check SRZN's fair value in chart for subscribers.

What is the fair value of SRZN stock?

You can check SRZN's fair value in chart for subscribers. The fair value of Surrozen, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Surrozen, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SRZN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Surrozen, Inc. a good stock to buy?

The fair value guage provides a quick view whether SRZN is over valued or under valued. Whether Surrozen, Inc. is cheap or expensive depends on the assumptions which impact Surrozen, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SRZN.

What is Surrozen, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 16 2024, SRZN's PE ratio (Price to Earnings) is -0.69 and Price to Sales (PS) ratio is 2.82. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SRZN PE ratio will change depending on the future growth rate expectations of investors.